SLU-PP-332 | Endurance Archives

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

This is the only characterization of how SLU-PP-332 is metabolized by human tissue. Researchers incubated the compound with human liver S9 fraction and human liver microsomes and used high-resolution tandem mass spectrometry to identify nine metabolites, six Phase-I and three Phase-II, alongside reference analytical data for the parent compound. The work was performed for sports drug testing purposes, which is directly relevant because SLU-PP-332 is a WADA prohibited substance and that status must be disclosed to athlete patients. It is human-tissue metabolism data rather than a dosing study, so it reports no oral bioavailability figure.

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Read Post »

Exercise in a Pill: Emerging Therapeutics for Age-Related Orthopedic Diseases.

This review examines exercise mimetics – drugs that can simulate the benefits of physical activity without actual exercise. As people age, orthopedic diseases often prevent them from exercising, creating a cycle where they can’t get the muscle and bone benefits that exercise provides. Exercise mimetic compounds like SLU-PP-332 could offer a pharmaceutical solution to help patients maintain musculoskeletal health when they’re unable to be physically active.

Exercise in a Pill: Emerging Therapeutics for Age-Related Orthopedic Diseases. Read Post »

Modulation of mitochondrial quality by exercise mimetics: A potential strategy for the prevention and treatment of Alzheimer’s disease.

This review examines how exercise mimetic compounds like SLU-PP-332 could help prevent and treat Alzheimer’s disease by improving cellular energy production. When brain cells can’t produce energy properly, it leads to the brain damage seen in Alzheimer’s. These compounds work by activating the same cellular pathways that exercise does, potentially offering benefits for patients who can’t exercise regularly. This suggests exercise mimetics could be a practical intervention for cognitive decline.

Modulation of mitochondrial quality by exercise mimetics: A potential strategy for the prevention and treatment of Alzheimer’s disease. Read Post »

[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].

This research review examines how activating estrogen-related receptors (ERRα/β/γ) can mimic the beneficial effects of physical exercise at the molecular level. The study focuses on SLU-PP-332, a compound that targets these receptors to potentially provide exercise-like metabolic benefits for patients who cannot engage in regular physical activity. This pharmacological approach could help address chronic diseases linked to sedentary lifestyles by activating the same cellular pathways that exercise normally triggers. The research suggests promise for treating metabolic dysfunction in physically inactive patients.

[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. Read Post »

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

Researchers investigated the effects of SLU-PP-332, a synthetic estrogen-related receptor (ERR) agonist, on metabolic syndrome in an animal model. The compound was found to alleviate metabolic syndrome symptoms, suggesting potential therapeutic applications for this drug target. This is animal model evidence and requires further human clinical investigation before applicability to patient care.

A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Read Post »

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

Researchers investigated whether SLU-PP-332, a synthetic agonist targeting estrogen-related receptors (ERRα/β/γ), could induce exercise-like metabolic responses in humans. The study found that SLU-PP-332 activated ERRα-dependent pathways that mimicked acute aerobic exercise responses and improved exercise capacity in human subjects. This is human clinical evidence demonstrating pharmacological activation of metabolic pathways associated with exercise adaptation.

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. Read Post »